Clinical reference Biomarker Directory
Back to directory

Interleukin-1 beta

Emerging

IL-1β drives several autoinflammatory diseases and is a direct target of anakinra/canakinumab; also studied in cardiovascular disease.

Also known as IL-1 beta interleukin-1 beta
In plain language

IL-1 beta drives fever and inflammation in several rare autoinflammatory diseases, and specific drugs block it directly. A landmark study also found that blocking this same molecule reduces heart attack and stroke risk, independent of cholesterol levels — suggesting inflammation itself might be a treatable heart disease risk factor.

Biomarker & context

Interleukin-1 beta (IL-1β) is a key pro-inflammatory cytokine that drives fever, tissue inflammation, and activation of the broader inflammatory cascade, central to several autoinflammatory diseases.

What it indicates

IL-1β is the direct therapeutic target of anakinra and canakinumab, used in conditions like familial Mediterranean fever, cryopyrin-associated periodic syndromes, and other autoinflammatory diseases driven by excess IL-1 signaling.

Diagnosis & clinical testing

IL-1β itself is not typically measured directly to guide treatment; diagnosis of the autoinflammatory conditions it drives relies on clinical criteria, genetic testing (for conditions like CAPS), and response to IL-1-blocking therapy as supportive confirmation.

Guiding treatment

Beyond autoinflammatory disease, IL-1β blockade (canakinumab) is increasingly investigated as an anti-inflammatory approach in cardiovascular disease following the CANTOS trial, which showed canakinumab reduced cardiovascular events independent of cholesterol lowering — a genuinely novel finding supporting inflammation itself as an independent cardiovascular treatment target.

Clinical significance

The CANTOS trial showed IL-1β blockade reduces cardiovascular events independent of cholesterol, a genuinely novel finding.

References
  1. General rheumatology and cardiology reference literature on IL-1β in autoinflammatory disease and the CANTOS cardiovascular trial.